A first-in-human phase I study of SAR650984, a humanized anti-CD38 antibody in patients with CD38+ hematological malignancies: Preliminary PK and PD results of escalation phase

Category Primary study
JournalCancer Research
Year 2014
This article has no abstract
Epistemonikos ID: 2e29a07bc2f055157933252dcf6ec8027ec8bd6d
First added on: Feb 06, 2025